This site is intended for healthcare professionals

Speciality hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 11th May 2020

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

Learning Zone Homepage

COMT inhibition in Parkinson’s Disease

The COMT inhibition in Parkinson's Disease Learning Zone contains key information, expert opinion and interactive learning to highlight the benefit to patients of early levodopa treatment and diagnosis of the motor fluctuations which signal disease progression and prompt adjunctive treatment. Also detailing key efficacy and safety data for the approved COMT inhibitors to help inform your treatment decisions.

Learning Zone Homepage

Spinal Muscular Atrophy

SMA is caused by loss of function mutations or deletions in the SMN1 gene, which results in insufficient levels of the survival of motor neuron (SMN) protein. Find out more here.

Learning Zone Homepage

Neuroscience and Pain Learning Zone

A focus on ADHD, Alzheimer's disease, epilepsy and pain. Videos within each section, world-leading experts will help you diagnose these often challenging conditions.

Related news and insights

Couldn’t make it to EAN 2020? Here’s what you missed

EAN 2020 recently brought together thousands of neurologists for four days of virtual sessions, ePosters and plenaries. If you couldn’t make it, catch-up on what you missed with our summary of the highlights from this year’s virtual EAN congress.

1 mins

FDA approval for Kynmobi for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease. Sunovion Pharma

Sunovion Pharmaceuticals Inc. has announced that the FDA has approved Kynmobi (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).

1 min

Results of GERAS-US Study shows societal cost burden for early stages of Alzheimer's disease.- Eli Lilly

Eli Lilly and Company announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild dementia (MILD), and caring for someone with Alzheimer's disease (AD).

2 min

See all news

Related drugs

Solpadeine Plus Tablets

Solpadeine Plus Tablets

Solpadeine Plus Capsules

Solpadeine Plus Capsules

solpadeine max tablets

solpadeine max tablets

Paramol Tablets

Paramol Tablets

Paracodol tablets

Paracodol tablets

Paracetamol 500mg Tablets (P)

Paracetamol 500mg Tablets (P)

Paracetamol 500mg Suppositories

Paracetamol 500mg Suppositories

Paracetamol 500mg Soluble Tablets

Paracetamol 500mg Soluble Tablets

Paracetamol 500 mg Caplets

Paracetamol 500 mg Caplets

Paracetamol 250mg/5ml Oral Suspension

Paracetamol 250mg/5ml Oral Suspension

Paracetamol 250mg Suppositories

Paracetamol 250mg Suppositories

Paracetamol 250 mg/5 ml Oral Suspension PL 04917/0029)

Paracetamol 250 mg/5 ml Oral Suspension PL 04917/0029)

Paracetamol 125mg Suppositories

Paracetamol 125mg Suppositories

Paracetamol 120mg/5ml Oral Suspension

Paracetamol 120mg/5ml Oral Suspension

Related Guidelines

Cannabis-based medicinal products

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

1 mins

Pharmacological management of migraine

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache.

1 min

End of life care for infants, children and young people with life-limiting conditions: planning and management

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families...

1 min

Read more

Your peers are looking at...

Phase III Archway study of Lucentis Port Delivery System meets primary endpoint in age-related macular degeneration.- Genentech/Roche

Phase III Archway study of Lucentis Port Delivery System meets primary endpoint in age-related macular degeneration.- Genentech/Roche

1 mins

FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer.- BMS

FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer.- BMS

1 mins

Aurinia Pharmaceuticals Inc.has completed the rolling submission to the FDA for voclosporin as a potential treatment for lupus nephritis.

Aurinia Pharmaceuticals Inc.has completed the rolling submission to the FDA for voclosporin as a potential treatment for lupus nephritis.

1 mins

Novartis announces at EAN new data for ofatumumab demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS).

Novartis announces at EAN new data for ofatumumab demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS).

4 mins

Novartis Kisqali shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease.

Novartis Kisqali shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease.

2 mins

Merck Inc., and Ridgeback Bio collaborate to advance development of novel antiviral candidate, EIDD-2801 to treat COVID-19 .

Merck Inc., and Ridgeback Bio collaborate to advance development of novel antiviral candidate, EIDD-2801 to treat COVID-19 .

1 mins

IAVI and Merck Inc., collaborate to develop vaccine against SARS-CoV-2.

IAVI and Merck Inc., collaborate to develop vaccine against SARS-CoV-2.

1 mins

Hansa Biopharma submits responses to outstanding questions from EMA for imlifidase application in kidney transplantation.

Hansa Biopharma submits responses to outstanding questions from EMA for imlifidase application in kidney transplantation.

1 mins

European Commission approves Zeposia to treat relapsing remitting multiple sclerosis.- BMS

European Commission approves Zeposia to treat relapsing remitting multiple sclerosis.- BMS

1 mins

Couldn’t make it to ASCO 2020? Here’s what you missed

Couldn’t make it to ASCO 2020? Here’s what you missed

1 mins

Related Journals

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

1 mins

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

1 mins

Emergency Management of Epilepsy and Seizures.

Emergency Management of Epilepsy and Seizures.

1 mins

Executive function in eating disorders: The role of state anxiety

Executive function in eating disorders: The role of state anxiety

1 mins

Alemtuzumab depletion failure can occur in multiple sclerosis.

Alemtuzumab depletion failure can occur in multiple sclerosis.

1 mins

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

1 mins

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

1 mins

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

1 mins

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

1 mins

How do Migraines Impact Patient Day-To-Day life? An Exploratory Analysis of Patient Reported Data From The Patientslikeme Community

How do Migraines Impact Patient Day-To-Day life? An Exploratory Analysis of Patient Reported Data From The Patientslikeme Community

1 mins

Related Events

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2020

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2020

Alzheimer's Association International Conference (AAIC) 2020

Alzheimer's Association International Conference (AAIC) 2020

European Academy of Neurology (EAN) 2020

European Academy of Neurology (EAN) 2020

Related Clinical Trials

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

3 mins

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

3 mins

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

3 mins

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

4 mins

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

3 mins

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

3 mins

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

1 mins

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

2 mins

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

2 mins

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

3 mins

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

3 mins

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

4 mins